<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">14676797</article-id><article-id pub-id-type="pmc">2395282</article-id><article-id pub-id-type="pii">6601419</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601419</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Trufflandier</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferri&#x000e8;re</surname><given-names>J M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Debled</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Palussi&#x000e8;re</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cany</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gaston</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mathoulin-P&#x000e9;lissier</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Bui</surname><given-names>B N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Department of Medicine, Institut Bergoni&#x000e9;, Bordeaux, France</aff><aff id="aff2"><label>2</label><sup>2</sup>Department of Urology, University Hospital, Bordeaux, France</aff><aff id="aff3"><label>3</label><sup>3</sup>Department of Radiology, Institut Bergoni&#x000e9;, Bordeaux, France</aff><aff id="aff4"><label>4</label><sup>4</sup>Department of Surgery, Institut Bergoni&#x000e9;, Bordeaux, France</aff><aff id="aff5"><label>5</label><sup>5</sup>Department of Urology, Clinique Saint Augustin, Bordeaux, France</aff><aff id="aff6"><label>6</label><sup>6</sup>Department of Biostatistics, Institut Bergoni&#x000e9;, Bordeaux, France</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:alain.ravaud@chu-bordeaux.fr">alain.ravaud@chu-bordeaux.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>12</month><year>2003</year></pub-date><pub-date pub-type="ppub"><day>15</day><month>12</month><year>2003</year></pub-date><volume>89</volume><issue>12</issue><fpage>2213</fpage><lpage>2218</lpage><history><date date-type="received"><day>04</day><month>08</month><year>2003</year></date><date date-type="rev-recd"><day>18</day><month>09</month><year>2003</year></date><date date-type="accepted"><day>23</day><month>09</month><year>2003</year></date></history><copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement><copyright-year>2003</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>immunotherapy</kwd><kwd>interleukin-2</kwd><kwd>interferon alpha</kwd><kwd>5-fluorouracil</kwd><kwd>renal cell carcinoma</kwd><kwd>second-line treatment</kwd></kwd-group></article-meta></front><body><p>The prognosis of patients with metastatic renal cell carcinoma (MRCC) remains poor with an estimated 5-year survival of 0&#x02013;20&#x00025; (<xref ref-type="other" rid="bib20">Linehan <italic>et al</italic>, 2001</xref>). Interferon alpha (IFN<italic>&#x003b1;</italic>) and interleukin-2 (IL-2) have shown objective responses in 10&#x02013;25&#x00025; of patients (<xref ref-type="other" rid="bib34">Rosenberg <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib2">Atzpodien <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib3">Buter <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib11">Fyfe <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib35">Savage and Muss, 1995</xref>; <xref ref-type="other" rid="bib40">Yang and Rosenberg, 1997</xref>; <xref ref-type="other" rid="bib28">N&#x000e9;grier <italic>et al</italic>, 1998</xref>) and long-lasting responders (<xref ref-type="other" rid="bib12">Fyfe <italic>et al</italic>, 1996</xref>). More recently, INF<italic>&#x003b1;</italic> has been shown to prolong survival compared to hormonotherapy (<xref ref-type="other" rid="bib23">Medical Research Council Renal Cancer Collaborators, 1999</xref>), although progression occurred in most patients.</p><p>When this study was designed, no effective second-line treatment arrising from chemotherapy (<xref ref-type="other" rid="bib39">Yagoda <italic>et al</italic>, 1995</xref>) or cellular therapy (<xref ref-type="other" rid="bib10">Figlin <italic>et al</italic>, 1998</xref>) was available. Only one study in 13 patients with MRCC treated with s.c. IL-2 after failure under IFN<italic>&#x003b1;</italic> reported four partial responses (<xref ref-type="other" rid="bib21">Lissoni <italic>et al</italic>, 1992</xref>).</p><p>Based on preclinical data suggesting a synergism between IL-2 and 5-fluorouracil (5-FU) on one hand and IFN<italic>&#x003b1;</italic> and 5-FU on the other, added to the well-known synergism of the association of IL-2 and IFN<italic>&#x003b1;</italic> (<xref ref-type="other" rid="bib4">Cameron <italic>et al</italic>, 1988</xref>), the combination of IL-2, IFN<italic>&#x003b1;</italic> and 5-FU has been investigated in renal cell carcinoma. In animal experiments, IL-2 potentiates the antitumoral activity of various cytotoxic drugs including 5-FU (<xref ref-type="other" rid="bib13">Gauny <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib18">Kawano <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib19">Lee <italic>et al</italic>, 1994</xref>). Modulation of 5-FU with IFN<italic>&#x003b1;</italic> has been more extensively studied. IFN<italic>&#x003b1;</italic> induces thymidine phosphorylase, enhancing the conversion of 5-FU to the active 5-fluorodeoxyuridine monophosphate (FdUMP) inducing the depletion of thymidine triphosphate pools and DNA breakpoint, leading so far to an increase of the cytoxicity of 5-FU (<xref ref-type="other" rid="bib38">Wadler <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib25">Morita and Tokue, 1999</xref>). Moreover, IFN<italic>&#x003b1;</italic> inhibits the intracellular uptake of thymidine (<xref ref-type="other" rid="bib31">Pfeffer and Tamm, 1984</xref>), and thymidilate synthase (<xref ref-type="other" rid="bib7">Elias and Sandoval, 1989</xref>). At the beginning of the 1990s, clinical trials reported an increased response rate when 5-FU was added to IL-2 and IFN<italic>&#x003b1;</italic> (<xref ref-type="other" rid="bib2">Atzpodien <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib15">Hofmockel <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib16">Joffe <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib8">Ellerhorst <italic>et al</italic>, 1997</xref>). Groups using an identical schedule as Atzpodien <italic>et al</italic> showed the response rate as ranging from 16 to 48&#x00025; (<xref ref-type="other" rid="bib2">Atzpodien <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib15">Hofmockel <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib16">Joffe <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib8">Ellerhorst <italic>et al</italic>, 1997</xref>).</p><p>Owing to the lack of a validated second-line treatment after immunotherapy in MRCC, the possibility that a second-line chemo-immunotherapy might prevent progression under previous immunotherapy was tested. Based on the reported higher response rate when 5-FU was added to IL-2 and IFN<italic>&#x003b1;</italic>, this study was designed to test the ability of the association of IL-2, IFN<italic>&#x003b1;</italic> and 5-FU to induce an objective response or at least stabilization while patients had progressed under IFN<italic>&#x003b1;</italic> and&#x0002f;or IL-2.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Patients</title><p>Eligible patients had histologically proven renal cell carcinoma with progressive metastatic disease after a previous immunotherapy with IFN<italic>&#x003b1;</italic> and&#x0002f;or IL-2. Patients were adults less than 75 years of age, who had a Karnofsky performance status &#x0003e;70&#x00025;. Patients were required to have measurable metastatic disease. They were not to have received either immunotherapy or radiotherapy in the previous 4 weeks. Adequate organ functions were required without cardiac, respiratory, hepatic, renal, neurologic or psychiatric disorders. They had normal blood cell counts, normal bilirubin level, creatinine concentrations less than 180&#x02009;<italic>&#x003bc;</italic>mol&#x0002f;l<sup>&#x02212;1</sup>, normal cardiac function and a life expectancy of at least 3 months. Patients with severe infection, known positivity of human immunodeficiency virus test or chronic hepatitis were excluded, as were patients on corticosteroids. Patients did not have history of an organ allograft or other malignancies. Pregnant or lactating women were also excluded.</p><p>The trial was approved by the CCPPRB in Bordeaux according to the French law. The study was conducted according to the principles of Good Clinical Practice.</p></sec><sec><title>Pretreatment evaluation</title><p>In addition, clinical history and physical examination were recorded for all patients. Preinclusion staging included cerebral, thoracic, abdominal CT scans and a bone scan. Written informed consent was obtained before inclusion in the trial.</p></sec><sec><title>Treatment plan (<xref rid="tbl1" ref-type="table">Table 1</xref>)</title><p>Interleukin-2 (Proleukin; Chiron Therapeutics, Suresnes, France) was given subcutaneously at a dose of 9 &#x000d7; 10<sup>6</sup>&#x02009;IU&#x02009;m<sup>&#x02212;2</sup>, twice on days 1 and 2, once a day on days 3&#x02013;5 and every other week for 8 weeks. Interferon alpha (Introna; Schering Plough, Levallois-Perret, France) was administered at a dose of 6 &#x000d7; 10<sup>6</sup>&#x02009;IU, three times a week, during weeks with IL-2. 5-Fluorouracil was delivered by a continuous infusion at 750&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> for five consecutive days every 4 weeks, starting with IL-2 and IFN<italic>&#x003b1;</italic> in the first week. Each time an objective response or a stable disease occurred, an additional identical course of treatment was given after 1 week's rest. <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Schedule and dose of treatment</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50">IL-2</td><td align="left" valign="top" charoff="50"><sup>&#x0002a;</sup></td><td align="left" valign="top" charoff="50"><sup>&#x0002a;</sup></td><td align="left" valign="top" charoff="50">&#x022c4;</td><td align="left" valign="top" charoff="50">&#x022c4;</td><td align="left" valign="top" charoff="50">&#x022c4;</td><td align="left" valign="top" charoff="50"><sup>&#x0002a;</sup></td><td align="left" valign="top" charoff="50"><sup>&#x0002a;</sup></td><td align="left" valign="top" charoff="50">&#x022c4;</td><td align="left" valign="top" charoff="50">&#x022c4;</td><td align="left" valign="top" charoff="50">&#x022c4;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">IFN<italic>&#x003b1;</italic></td><td align="left" valign="top" charoff="50">&#x00023;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x00023;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x00023;</td><td align="left" valign="top" charoff="50">&#x00023;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x00023;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x00023;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">5-FU</td><td align="left" valign="top" charoff="50">&#x003c6;</td><td align="left" valign="top" charoff="50">&#x003c6;</td><td align="left" valign="top" charoff="50">&#x003c6;</td><td align="left" valign="top" charoff="50">&#x003c6;</td><td align="left" valign="top" charoff="50">&#x003c6;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">day</td><td align="left" valign="top" charoff="50">1</td><td align="left" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">4</td><td align="left" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">15</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">17</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">19</td><td align="left" valign="top" charoff="50">29</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Second cycle</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label>&#x0002a;</label><p>&#x0003d;IL-2: 9 &#x000d7; 10<sup>6</sup>&#x02009;IU&#x02009;m<sup>&#x02212;2</sup> &#x000d7; 2, &#x022c4;&#x0003d;IL-2: 9 &#x000d7; 10<sup>6</sup>&#x02009;IU&#x02009;m<sup>&#x02212;2</sup>, &#x00023;&#x0003d;IFN<italic>&#x003b1;</italic>: 6 &#x000d7; 10<sup>6</sup>&#x02009;IU, &#x003c6;&#x0003d;5-FU 750&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Evaluation of treatment</title><p>Evaluation of tumour response, including thoracic and abdominal CT-scan and a bone scan, was performed every 8 weeks of treatment. The World Health Organization (WHO) criteria were used to determine tumour response (<xref ref-type="other" rid="bib24">Miller <italic>et al</italic>, 1981</xref>). Complete response (CR) was defined as the complete disappearance of all measurable and evaluable tumour sites for at least 4 weeks. The duration of CR was calculated from the first date of documentation of CR to the date of the first evaluation of disease progression. Partial response (PR) was considered to be a &#x02a7e;50&#x00025; decrease in the sum of products of the greatest perpendicular diameters lasting for at least 4 weeks, with no increase in known lesions and without appearance of any new lesions. When the evaluation showed a &#x0003c;50&#x00025; decrease in lesions or a &#x0003c;25&#x00025; increase, patients were considered to have a stable disease (SD). The duration of PR and SD was calculated from the first day of treatment. Progressive disease (PD) was considered to be when any lesion increased by &#x02a7e;25&#x00025; or when a new lesion appeared. The results of the successive bone scans were considered as PD in the case of appearance of new spots, stable if not, and complete regression only if all spots disappeared. Patients who presented with a CR, PR or SD were evaluated every 2&#x02013;3 months during the first year and then every 4&#x02013;6 months.</p><p>Survival duration was evaluated from the start of treatment to the date of the last contact or the date of death. Progression-free survival was calculated from the start of treatment to the date of last follow-up or the date of progression.</p><p>Toxicities encountered were classified according to the WHO grading system.</p></sec><sec><title>Statistical analysis</title><p>The primary end point was the response rate. The secondary end points were stabilisation rate, prolonged stabilisation rate (at least a period following chemo-immunotherapy as long as two cycles of treatment: 2 &#x000d7; &#x0005b;2 &#x000d7; 8 weeks&#x0005d;&#x0003d;32 weeks or 8 months), overall survival, toxicity and prognostic factors for progression under second-line chemo-immunotherapy and overall survival.</p><p>The trial was conducted according to the two-stage Gehan design (<xref ref-type="other" rid="bib14">Gehan, 1961</xref>). As first-line treatment, IFN<italic>&#x003b1;</italic> and IL-2 have shown objective responses in 18&#x00025; of patients included into trials that we conducted (<xref ref-type="other" rid="bib28">N&#x000e9;grier <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib33">Ravaud <italic>et al</italic>, 1994</xref>); we planned to detect a response rate &#x02a7e;10&#x00025;. We assessed the response rate after 29 patients had been recruited to have a 95&#x00025; chance of detecting at least one response when the actual response rate was &#x02a7e;10&#x00025;. If at least one response occurred in the first 29 patients, we planned to increase the number of patients to assess the response rate with 5&#x00025; precision (i.e., one response justified the inclusion of four more patients: at least 33 patients for the study).</p><p>To study prognostic factors, patients presenting response and stabilisation were pooled. Progressive disease was considered in the case of progression of the disease at tumour evaluation performed at 8 weeks. The following potential clinical prognostic parameters were analysed: gender, time from primary tumor to occurrence of metastases (&#x0003c;12 months <italic>vs</italic> &#x02a7e;12 months), type of first-line immunotherapy (IL-2 <italic>vs</italic> IFN<italic>&#x003b1;</italic> alone), response to first-line immunotherapy (PD <italic>vs</italic> objective response or stabilisation), number of sites before second-line treatment (1 <italic>vs</italic> &#x0003e;1) and general status (Karnofsky &#x02a7e;90&#x00025; <italic>vs</italic> &#x0003c;90&#x00025;). The association between response and stabilisation after second-line immunotherapy was assessed using the <italic>&#x003c7;</italic><sup>2</sup> test and survival distribution was estimated using the Kaplan&#x02013;Meier method (<xref ref-type="other" rid="bib17">Kaplan and Meier, 1958</xref>). The relationship between survival and parameters was analysed with the log-rank test (<xref ref-type="other" rid="bib22">Mantel, 1966</xref>). Parameters that were significantly associated with survival at a <italic>P</italic>-value of &#x0003c;0.10 were included in a forward stepwise Cox model (<xref ref-type="other" rid="bib22">Mantel, 1966</xref>).</p></sec></sec><sec><title>RESULTS</title><sec><title>Patient characteristics</title><p>From September 1994 to April 2000, 35 patients with MRCC were entered into the trial. All patients were evaluable for response and for toxicity and their main characteristics are outlined in <xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Characteristics of patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristics</bold></th><th align="center" valign="top" charoff="50"><bold>No.</bold></th><th align="left" valign="top" charoff="50"><bold>&#x00025;</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Eligible patients</td><td align="center" valign="top" charoff="50">35</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Patients assessable</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;for toxicity</td><td align="center" valign="top" charoff="50">35</td><td align="left" valign="top" charoff="50">100</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;for response</td><td align="center" valign="top" charoff="50">35</td><td align="left" valign="top" charoff="50">100</td></tr><tr><td align="left" valign="top" charoff="50">Men&#x0002f;women</td><td align="center" valign="top" charoff="50">27&#x0002f;8</td><td align="left" valign="top" charoff="50">77&#x0002f;23</td></tr><tr><td align="left" valign="top" charoff="50">Age (years) median (range)</td><td align="center" valign="top" charoff="50">62 (25&#x02013;75)</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Performance status (Karnofsky)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;100&#x00025;</td><td align="center" valign="top" charoff="50">7</td><td align="left" valign="top" charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;90&#x00025;</td><td align="center" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">40</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;80&#x00025;</td><td align="center" valign="top" charoff="50">12</td><td align="left" valign="top" charoff="50">34.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;70&#x00025;</td><td align="center" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">5.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Time from diagnosis to first metastases</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;12 months</td><td align="center" valign="top" charoff="50">25</td><td align="left" valign="top" charoff="50">71.4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;12 months</td><td align="center" valign="top" charoff="50">10</td><td align="left" valign="top" charoff="50">28.6</td></tr><tr><td align="left" valign="top" charoff="50">Prior nephrectomy</td><td align="center" valign="top" charoff="50">35</td><td align="left" valign="top" charoff="50">100</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Prior immunotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IFN</td><td align="center" valign="top" charoff="50">21</td><td align="left" valign="top" charoff="50">60</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IL-2</td><td align="center" valign="top" charoff="50">9</td><td align="left" valign="top" charoff="50">25.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IL-2&#x0002b;IFN</td><td align="center" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">14.3</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Response to first-line immunotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IFN (CR, PR, SD, PD)</td><td align="center" valign="top" charoff="50">1, 2, 12, 6</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IL-2 (CR, PR, SD, PD)</td><td align="center" valign="top" charoff="50">0, 1, 4, 4</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IL-2&#x0002b;IFN (CR, PR, SD, PD)</td><td align="center" valign="top" charoff="50">0, 2, 2, 1</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Site of metastatic disease</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung</td><td align="center" valign="top" charoff="50">27</td><td align="left" valign="top" charoff="50">77.1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mediastinal lymph nodes</td><td align="center" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">40</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bone</td><td align="center" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Abdominal lymph nodes</td><td align="center" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="center" valign="top" charoff="50">4</td><td align="left" valign="top" charoff="50">11</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Recurrence at nephrectomy site</td><td align="center" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Others</td><td align="center" valign="top" charoff="50">8</td><td align="left" valign="top" charoff="50">23</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Number of sites with metastases</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">9</td><td align="left" valign="top" charoff="50">25.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;1</td><td align="center" valign="top" charoff="50">26</td><td align="left" valign="top" charoff="50">74.3</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote2"><label/><p>IFN&#x0003d;interferon, IL-2&#x0003d;interleukin-2, CR&#x0003d;complete response, PR&#x0003d;partial response, SD&#x0003d;stable disease, PD&#x0003d;progressive disease.</p></fn></table-wrap-foot></table-wrap>. Most patients had an ambulatory performance status: 21 patients (60&#x00025;) had a Karnofsky performance status &#x02a7e;90&#x00025;, while 14 (40&#x00025;) patients had a Karnofsky performance status &#x0003c;90&#x00025;. The time from diagnosis of renal cell carcinoma to the occurrence of metastases was less than 12 months in 25 patients (71.4&#x00025;). All patients had a prior nephrectomy. The median delay from diagnosis of metastatic disease to first immunotherapy was 3.4 months (range: 0&#x02013;29 months). For the first-line immunotherapy, 21 patients were treated with IFN<italic>&#x003b1;</italic>, nine with IL-2 and five with the association of IFN<italic>&#x003b1;</italic> and IL-2. Six patients (17.2&#x00025;) showed an objective response (1 CR and 5 PR), while 18 (51.4&#x00025;) had a SD. In a median time of 9 months (range: 2&#x02013;77 months), patients were included in this study. At the time of second-line treatment, the metastatic disease was localised in the lung (27 patients), mediastinal or abdominal lymph nodes (17 patients), bone (six patients), liver (four patients) and at the nephrectomy site (three patients). In all, 26 patients (74&#x00025;) had at least two tumour sites at the time of second-line treatment initiation.</p></sec><sec><title>Administration of treatment and toxicity</title><p>During cycles, the median dose given to patients was 100&#x00025; for each drug. The main toxicities (<xref rid="tbl3" ref-type="table">Table 3</xref>
 <table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Toxicity</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" charoff="50"><bold>Number of patients (&#x00025;) with toxicities by WHO grades I, II, III and IV</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50"><bold>I (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>II (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>III &#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>IV (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Decrease in performance status</td><td align="left" valign="top" charoff="50">8 (23)</td><td align="left" valign="top" charoff="50">17 (49)</td><td align="left" valign="top" charoff="50">3 (9)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Fever</td><td align="left" valign="top" charoff="50">1 (3)</td><td align="left" valign="top" charoff="50">17 (49)</td><td align="left" valign="top" charoff="50">6 (17)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="left" valign="top" charoff="50">8 (23)</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Nausea&#x0002f;vomiting</td><td align="left" valign="top" charoff="50">5 (14)</td><td align="left" valign="top" charoff="50">8 (23)</td><td align="left" valign="top" charoff="50">4 (11)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Local skin pain</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">General skin disorders</td><td align="left" valign="top" charoff="50">5 (14)</td><td align="left" valign="top" charoff="50">5 (14)</td><td align="left" valign="top" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Hypotension</td><td align="left" valign="top" charoff="50">1 (3)</td><td align="left" valign="top" charoff="50">4 (11)</td><td align="left" valign="top" charoff="50">3 (9)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Mucositis</td><td align="left" valign="top" charoff="50">3 (9)</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Cardiotoxicity</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Neurological</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">1 (3)</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Psychiatric</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">3 (9)</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Infection</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Weight gain</td><td align="left" valign="top" charoff="50">1 (3)</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Haematological</td><td align="left" valign="top" charoff="50">5 (14)</td><td align="left" valign="top" charoff="50">4 (11)</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Increase in transaminases</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Hypercreatininaemia</td><td align="left" valign="top" charoff="50">2 (6)</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Others</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">4 (11)</td><td align="left" valign="top" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table></table-wrap>) were decrease in performance status (28 patients, 80&#x00025;), fever (24 patients, 69&#x00025;), nausea&#x0002f;vomiting (17 patients, 49&#x00025;), diarrhoea (12 patients, 34&#x00025;), cutaneous erythema (11 patients, 31&#x00025;), hypotension (eight patients, 23&#x00025;) and haematological disturbances (11 patients, 31&#x00025;). In all, 17 patients (49&#x00025;) had treatment-related grade 3 toxicity; 27 grade 3 events were reported: fever (six patients, 17&#x00025;), nausea&#x0002f;vomiting (four patients, 11&#x00025;), decrease in performance status, hypotension (three patients, 9&#x00025;), diarrhoea, cardiotoxicity, mucositis (two patients) and skin erythema, anaemia, neutropenia and hypothyroidism (one patient). Nevertheless, none had grade 4 toxicity or died within the treatment course.</p></sec><sec><title>Response to treatment and survival</title><p>The median follow-up was 14 months. At the evaluation performed after 8 weeks of treatment, two patients (5.7&#x00025;; 95&#x00025; CI: 0.07&#x02013;19.15&#x00025;) had achieved an objective response, with one CR obtained after an immediate subsequent mediastinal radiotherapy. The duration of response was 6 and 56&#x0002b; months. In all, 14 patients (40&#x00025;; 95&#x00025; CI: 23.8&#x02013;57.9&#x00025;) had SD for a median time of 4 months (range: 2&#x02013;16 months), including four patients (11.4&#x00025;) with SD &#x0003e;8 months, while 19 showed disease progression. The sites of response were lung and lymph nodes for both patients. The median survival of all patients was 14 months (95&#x00025; CI: 10.4&#x02013;17.7 months) (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Overall survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601419f1"/></fig>). Patients who showed stabilisation or an objective response had a median survival of 22 months (95&#x00025; CI: 10.2&#x02013;33.8 months), while those with a PD had a median survival of 9 months (95&#x00025; CI: 4.7&#x02013;13.3 months).</p></sec><sec><title>Predictive factors for progression to second-line immunotherapy</title><p>In univariate analysis, only the results of primary immunotherapy: stabilisation or objective response <italic>vs</italic> progression were significantly predictive for PD under second-line immunotherapy treatment (<italic>&#x003c7;</italic><sup>2</sup>, <italic>P</italic>: 0.026). Neither gender, time from primary tumour to occurrence of metastases (&#x0003c;12 months <italic>vs</italic> &#x02a7e;12 months), type of first-line immunotherapy (IL-2-based treatment <italic>vs</italic> IFN<italic>&#x003b1;</italic> alone), number of sites before second-line treatment (1 <italic>vs</italic> &#x0003e;1) nor general status (Karnofsky &#x02a7e;90 <italic>vs</italic> &#x0003c;90&#x00025;) reached statistical significance.</p></sec><sec><title>Predictive factors for survival following second-line immunotherapy</title><p>In univariate analysis, factors significantly (<italic>P</italic>&#x0003c;0.05) associated with better survival were objective response or stabilisation after second-line treatment (<italic>P</italic>&#x0003c;0.001) and general status at the time of second-line treatment (<italic>P</italic>&#x0003c;0.01). Neither the type of first-line immunotherapy nor the number of sites at second-line treatment was predictive of outcome.</p><p>Parameters showing an association with survival in univariate analysis with a degree of significance &#x0003c;0.10 were included in a forward stepwise Cox mutivariate analysis. General performance status (Karnofsky &#x02a7e;90&#x00025; <italic>vs</italic> &#x0003c;90&#x00025;) (<italic>P</italic>: 0.003), time from primary tumour to metastases (<italic>P</italic>: 0.033) and response or stabilisation to second-line treatment (<italic>P</italic>: 0.038) were considered as independent factors predictive of survival (<xref rid="tbl4" ref-type="table">Table 4</xref>
 <table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Univariate and multivariate stepwise Cox model analysis of survival for all patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="char" char="&#x02013;"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>Univariate</bold></th><th colspan="3" align="center" valign="top" charoff="50"><bold>Multivariate</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Prognostic factor</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic></bold></th><th align="center" valign="top" charoff="50"><bold>HR</bold></th><th align="char" valign="top" char="&#x02013;" charoff="50"><bold>95&#x00025; CI</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Objective response and stabilisation to second&#x02013;line immunotherapy with IL-2, IFN<italic>&#x003b1;</italic> and 5-FU</td><td align="center" valign="top" charoff="50">0.006</td><td align="center" valign="top" charoff="50">2.43</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.05&#x02013;5.6</td><td align="center" valign="top" charoff="50">0.038</td></tr><tr><td align="left" valign="top" charoff="50">General performance status (Karnofsky &#x02a7e;90 <italic>vs</italic> &#x0003c;90&#x00025;)</td><td align="center" valign="top" charoff="50">0.007</td><td align="center" valign="top" charoff="50">3.72</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.55&#x02013;8.91</td><td align="center" valign="top" charoff="50">0.003</td></tr><tr><td align="left" valign="top" charoff="50">Time interval from primary tumour to occurrence of metastases (&#x02a7d;12 <italic>vs</italic> &#x0003e;12 months)</td><td align="center" valign="top" charoff="50">0.07</td><td align="center" valign="top" charoff="50">2.71</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.08&#x02013;6.78</td><td align="center" valign="top" charoff="50">0.033</td></tr></tbody></table></table-wrap>).</p></sec></sec><sec><title>DISCUSSION</title><p>The RR obtained in this study after a second-line immunotherapy-based treatment remains low (two out of 35 patients) despite one prolonged complete remission (&#x0003e;56 months). Since the start of the study, only two other studies have examined this theme (<xref ref-type="other" rid="bib30">Paolorossi <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib9">Escudier <italic>et al</italic>, 1999</xref>). A large study in 113 patients confirmed the low response (four patients, 3.5&#x00025;) and stabilisation (13 patients, 11.5&#x00025;) rates, following a switch from IFN<italic>&#x003b1;</italic> to IL-2 and from IL-2 to IFN<italic>&#x003b1;</italic> after failure of the first-line cytokine therapy (<xref ref-type="other" rid="bib9">Escudier <italic>et al</italic>, 1999</xref>). In the former study (<xref ref-type="other" rid="bib9">Escudier <italic>et al</italic>, 1999</xref>), none of the patients received the association of both cytokines after one had already failed. In another study (<xref ref-type="other" rid="bib30">Paolorossi <italic>et al</italic>, 1995</xref>) following the initial work of <xref ref-type="other" rid="bib21">Lissoni <italic>et al</italic> (1992)</xref>, 15 patients received IFN<italic>&#x003b1;</italic> and vinblastine after failure under IL-2. Two patients showed an objective response and five had stabilisation (<xref ref-type="other" rid="bib30">Paolorossi <italic>et al</italic>, 1995</xref>).</p><p>Nevertheless, the occurrence of stabilisation in these circumstances, second-line treatment in patients, especially while they are still in a good general performance status (Karnofsky &#x02a7e;90&#x00025;) and when no alternative second-line treatment for renal cell carcinoma is available other than inclusion in clinical trials, could be considered to be of clinical interest. Furthermore, in this study, those patients with stabilisation or an objective response had a prolonged median survival of 22 months even after a second-line treatment. Nevertheless, spontaneous slow progression and&#x0002f;or long stabilisation of renal cell carcinoma without any antitumoral treatment may affect interpretation of survival outside compared phase III clinical trials. For this reason, it was considered useful when making decisions to point out predictive factors for outcome following a second-line immunotherapy-based treatment. This study shows that the most clinical significant predictive factor for no progressive disease at 8 weeks under second-line chemo-immunotherapy is the efficacy of first-line immunotherapy, which has not been assessed until now. Only one study reported that only patients with SD or transient responders with first-line cytokine treatment were responders (three out of four responders among 113 treated patients) (<xref ref-type="other" rid="bib9">Escudier <italic>et al</italic>, 1999</xref>). In our study, parameters favourably affecting survival were a good general performance status at initiation of second-line treatment (Karnofsky &#x02a7e;90&#x00025;), the delay from primary tumour to metastases (&#x0003e;12 months) and the response to second-line treatment. Previous studies on prognostic factors for survival in MRCC, especially those carried out in patients under immunotherapy, showed both general performance status and delay from primary tumour to metastases to affect survival significantly (<xref ref-type="other" rid="bib29">Palmer <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib27">N&#x000e9;grier <italic>et al</italic>, 2002</xref>). As the efficacy of second-line immunotherapy-based treatment was significantly correlated to the efficacy of the first-line treatment and as the second-line treatment had a significant impact on survival, it would have been helpful to study the correlation of survival to the first-line treatment, but the study was not designed for this purpose.</p><p>While a second-line immunotherapy-based treatment may be considered in selected patients, this study does not provide sufficient evidence that the association of IL-2, IFN<italic>&#x003b1;</italic> and 5-FU and the schedule used are a standard. This protocol is closely related to the schedule designed for other clinical research trials with IL-2, IFN<italic>&#x003b1;</italic> and &#x000b1;5-FU within the framework of the French Immunotherapy Group (<xref ref-type="other" rid="bib32">Ravaud <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib26">N&#x000e9;grier <italic>et al</italic>, 2000</xref>). These large studies showed an unexpectedly low response rate (<xref ref-type="other" rid="bib32">Ravaud <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib26">N&#x000e9;grier <italic>et al</italic>, 2000</xref>) like the present study, compared to more promising results obtained by others (<xref ref-type="other" rid="bib2">Atzpodien <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib15">Hofmockel <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib16">Joffe <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib8">Ellerhorst <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib36">Tourani <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib1">Allen <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib5">Dutcher <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib6">Elias <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib37">van Herpen <italic>et al</italic>, 2000</xref>).</p><p>Toxicities encountered by patients during this study were moderate as expected with no grade 4 WHO toxicity and 49&#x00025; of grade 3. Although the study was performed with second-line treatment, the toxicity profile did not show any differences compared to trials performed with first-line treatment (<xref ref-type="other" rid="bib32">Ravaud <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib26">N&#x000e9;grier <italic>et al</italic>, 2000</xref>).</p><p>In conclusion, we achieved 5.7&#x00025; of objective response and 40&#x00025; of stabilisation including 11.4&#x00025; prolonged stabilisation &#x0003e;8 months with IL-2, IFN<italic>&#x003b1;</italic>, 5-FU in patients with renal cell carcinoma in whom previous first-line immunotherapy failed. Therefore, the clinical benefit has to be considered as limited. Nevertheless, second-line immunotherapy may be considered only for selected patients who show either stabilisation or an objective response at evaluation of first-line immunotherapy, who have a good general status and a delay from the primary tumour to metastasis longer than 12 months. The recommended protocol therefore requires further evaluation.</p></sec></body><back><ack><p>We are indebted to the nurses of the department of medical oncology at Institut Bergoni&#x000e9; who provided the patients with excellent and compassionate care, Christine Dupouy, V&#x000e9;ronique Picot for the data management and Doroth&#x000e9;e Quincy for assistance in preparing the manuscript.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>MJ</given-names></name><name><surname>Vaughan</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Johnston</surname><given-names>S</given-names></name><name><surname>Savage</surname><given-names>P</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Bate</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Ahern</surname><given-names>R</given-names></name><name><surname>Gore</surname><given-names>ME</given-names></name></person-group><article-title>Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study</article-title><source>Br J Cancer</source><year>2000</year><volume>83</volume><fpage>980</fpage><lpage>985</lpage><!--PubMed citation query: 'Br J Cancer||83|980||bib1|'--><pub-id pub-id-type="pmid">10993642</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atzpodien</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>H</given-names></name><name><surname>Hanninen</surname><given-names>EL</given-names></name><name><surname>Korfer</surname><given-names>A</given-names></name><name><surname>Fenner</surname><given-names>M</given-names></name><name><surname>Menzel</surname><given-names>T</given-names></name><name><surname>Deckert</surname><given-names>M</given-names></name><name><surname>Franzke</surname><given-names>A</given-names></name><name><surname>Jonas</surname><given-names>U</given-names></name><name><surname>Poliwoda</surname><given-names>H</given-names></name></person-group><article-title>European studies of interleukin-2 in metastatic renal cell carcinoma</article-title><source>Semin Oncol</source><year>1993</year><volume>20</volume><supplement>Suppl 9</supplement><fpage>22</fpage><lpage>26</lpage><!--PubMed citation query: 'Semin Oncol||20|22||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buter</surname><given-names>J</given-names></name><name><surname>Sleijfer</surname><given-names>DT</given-names></name><name><surname>van der Graaf</surname><given-names>WT</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><name><surname>Willemse</surname><given-names>PH</given-names></name><name><surname>Mulder</surname><given-names>NH</given-names></name></person-group><article-title>A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2</article-title><source>Semin Oncol</source><year>1993</year><volume>20</volume><fpage>16</fpage><lpage>21</lpage><!--PubMed citation query: 'Semin Oncol||20|16||bib3|'--></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>RB</given-names></name><name><surname>McIntosh</surname><given-names>JK</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases</article-title><source>Cancer Res</source><year>1988</year><volume>48</volume><fpage>5810</fpage><lpage>5817</lpage><!--PubMed citation query: 'Cancer Res||48|5810||bib4|'--><pub-id pub-id-type="pmid">3262413</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dutcher</surname><given-names>JP</given-names></name><name><surname>Logan</surname><given-names>T</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Sosman</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Margolin</surname><given-names>K</given-names></name><name><surname>Plasse</surname><given-names>T</given-names></name><name><surname>Mier</surname><given-names>J</given-names></name><name><surname>Lotze</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Atkins</surname><given-names>M</given-names></name></person-group><article-title>Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>3442</fpage><lpage>3450</lpage><!--PubMed citation query: 'Clin Cancer Res||6|3442||bib5|'--><pub-id pub-id-type="pmid">10999727</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>L</given-names></name><name><surname>Lew</surname><given-names>D</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Flanigan</surname><given-names>RC</given-names></name><name><surname>Thompson</surname><given-names>ME</given-names></name><name><surname>Triozzi</surname><given-names>PL</given-names></name><name><surname>Belt</surname><given-names>RJ</given-names></name><name><surname>Wood</surname><given-names>DP</given-names><suffix>Jr</suffix></name><name><surname>Rivkin</surname><given-names>SE</given-names></name><name><surname>David</surname><given-names>E</given-names></name></person-group><article-title>Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>597</fpage><lpage>603</lpage><!--PubMed citation query: 'Cancer||89|597||bib6|'--><pub-id pub-id-type="pmid">10931459</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>L</given-names></name><name><surname>Sandoval</surname><given-names>JM</given-names></name></person-group><article-title>Interferon effects upon fluorouracil metabolism by HL-60 cells</article-title><source>Biochem Biophys Res Commun</source><year>1989</year><volume>163</volume><fpage>867</fpage><lpage>874</lpage><!--PubMed citation query: 'Biochem Biophys Res Commun||163|867||bib7|'--><pub-id pub-id-type="pmid">2783128</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellerhorst</surname><given-names>JA</given-names></name><name><surname>Sella</surname><given-names>A</given-names></name><name><surname>Amato</surname><given-names>RJ</given-names></name><name><surname>Tu</surname><given-names>SM</given-names></name><name><surname>Millikan</surname><given-names>RE</given-names></name><name><surname>Finn</surname><given-names>LD</given-names></name><name><surname>Banks</surname><given-names>M</given-names></name><name><surname>Logothetis</surname><given-names>CJ</given-names></name></person-group><article-title>Phase II trial of 5-fluorouracil, interferon-<italic>&#x003b1;</italic> and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma</article-title><source>Cancer</source><year>1997</year><volume>80</volume><fpage>2128</fpage><lpage>2132</lpage><!--PubMed citation query: 'Cancer||80|2128||bib8|'--><pub-id pub-id-type="pmid">9392335</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Lasset</surname><given-names>C</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Fabbro</surname><given-names>M</given-names></name><name><surname>Caty</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>JF</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Bergerat</surname><given-names>JP</given-names></name><name><surname>Savary</surname><given-names>J</given-names></name><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name></person-group><article-title>Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment?. Groupe Francais d'Immunoth&#x000e9;rapie</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2039</fpage><lpage>2143</lpage><!--PubMed citation query: 'J Clin Oncol||17|2039||bib9|'--><pub-id pub-id-type="pmid">10561255</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Figlin</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Roudet</surname><given-names>C</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Belldegrun</surname><given-names>A</given-names></name></person-group><article-title>Multi-center randomized placebo controlled phase II&#x0002f;III trial of CD8(&#x0002b;) tumor infiltrating lymphocyte therapy (CD8(&#x0002b;)TIL)&#x0002f;recombinant interleukin-2 (IL-2) in metastatic renal cell carcinoma (MRCC)</article-title><source>Proc Am Soc Clin Oncol</source><year>1998</year><volume>17</volume><fpage>1225</fpage>(abstract)<!--PubMed citation query: 'Proc Am Soc Clin Oncol||17|1225||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fyfe</surname><given-names>G</given-names></name><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>Parkinson</surname><given-names>DR</given-names></name><name><surname>Louie</surname><given-names>AC</given-names></name></person-group><article-title>Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>688</fpage><lpage>696</lpage><!--PubMed citation query: 'J Clin Oncol||13|688||bib11|'--><pub-id pub-id-type="pmid">7884429</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fyfe</surname><given-names>GA</given-names></name><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>Parkinson</surname><given-names>DR</given-names></name><name><surname>Louie</surname><given-names>AC</given-names></name></person-group><article-title>Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>2410</fpage><lpage>2411</lpage><!--PubMed citation query: 'J Clin Oncol||14|2410||bib12|'--><pub-id pub-id-type="pmid">8708739</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauny</surname><given-names>S</given-names></name><name><surname>Zimmerman</surname><given-names>RJ</given-names></name><name><surname>Winkelhake</surname><given-names>JL</given-names></name></person-group><article-title>Combination therapies using interleukin-2 and chemotherapeutics in murine tumors</article-title><source>Proc Am Assoc Cancer Res</source><year>1989</year><volume>30</volume><fpage>372</fpage>(abstract 1475)<!--PubMed citation query: 'Proc Am Assoc Cancer Res||30|372||bib13|'--></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gehan</surname><given-names>EA</given-names></name></person-group><article-title>The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent</article-title><source>J Chron Dis</source><year>1961</year><volume>13</volume><fpage>346</fpage><lpage>353</lpage><!--PubMed citation query: 'J Chron Dis||13|346||bib14|'--></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofmockel</surname><given-names>G</given-names></name><name><surname>Langer</surname><given-names>W</given-names></name><name><surname>Theiss</surname><given-names>M</given-names></name><name><surname>Gruss</surname><given-names>A</given-names></name><name><surname>Frohmuller</surname><given-names>HG</given-names></name></person-group><article-title>Immuno-chemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-<italic>&#x003b1;</italic> and 5-fluorouracil</article-title><source>J Urol</source><year>1996</year><volume>156</volume><fpage>18</fpage><lpage>21</lpage><!--PubMed citation query: 'J Urol||156|18||bib15|'--><pub-id pub-id-type="pmid">8648791</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joffe</surname><given-names>JK</given-names></name><name><surname>Banks</surname><given-names>RE</given-names></name><name><surname>Forbes</surname><given-names>MA</given-names></name><name><surname>Hallam</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>PM</given-names></name><name><surname>Hall</surname><given-names>GD</given-names></name><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Crossley</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>PW</given-names></name><name><surname>Whicher</surname><given-names>JT</given-names></name><name><surname>Selby</surname><given-names>PJ</given-names></name></person-group><article-title>A phase II study of interferon-<italic>&#x003b1;</italic>, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation</article-title><source>Br J Urol</source><year>1996</year><volume>77</volume><fpage>638</fpage><lpage>649</lpage><!--PubMed citation query: 'Br J Urol||77|638||bib16|'--><pub-id pub-id-type="pmid">8689103</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Non-parametric estimation from incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage><!--PubMed citation query: 'J Am Stat Assoc||53|457||bib17|'--></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Kuo</surname><given-names>T</given-names></name><name><surname>Kawamoto</surname><given-names>K</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Yasui</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Teramoto</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Kitajima</surname><given-names>M</given-names></name></person-group><article-title>Synergistic antitumor activity of interleukin-2, mitomycin C and 5-fluorouracil against colon cancer</article-title><source>Proc Am Assoc Cancer Res</source><year>1994</year><volume>35</volume><fpage>323</fpage>(abstract 1920)<!--PubMed citation query: 'Proc Am Assoc Cancer Res||35|323||bib18|'--></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>A</given-names></name><name><surname>Mahaffey</surname><given-names>W</given-names></name><name><surname>Specht</surname><given-names>S</given-names></name><name><surname>Stemmler</surname><given-names>N</given-names></name><name><surname>Katoh</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil, leucovorin and interleukin-2</article-title><source>Anticancer Drugs</source><year>1994</year><volume>5</volume><fpage>239</fpage><lpage>243</lpage><!--PubMed citation query: 'Anticancer Drugs||5|239||bib19|'--><pub-id pub-id-type="pmid">8049506</pub-id></citation></ref><ref id="bib20"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name><name><surname>Bates</surname><given-names>SE</given-names></name><name><surname>Zelefsky</surname><given-names>MJ</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name></person-group><article-title>Cancer of the kidney and ureter</article-title><source>Cancer: Principles &#x00026; Practice in Oncology</source><year>2001</year><publisher-name>Philadelphia: Lippincott Williams Wilkins</publisher-name><fpage>1362</fpage><lpage>1383</lpage>6th edn, DeVita VT, Helmann S, Rosenberg SA (eds) pp</citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lissoni</surname><given-names>P</given-names></name><name><surname>Barni</surname><given-names>S</given-names></name><name><surname>Ardizzoia</surname><given-names>A</given-names></name><name><surname>Crispino</surname><given-names>S</given-names></name><name><surname>Paolorossi</surname><given-names>F</given-names></name><name><surname>Archili</surname><given-names>C</given-names></name><name><surname>Vaghi</surname><given-names>M</given-names></name><name><surname>Tancini</surname><given-names>G</given-names></name></person-group><article-title>Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha</article-title><source>Eur J Cancer</source><year>1992</year><volume>28</volume><fpage>92</fpage><lpage>96</lpage><!--PubMed citation query: 'Eur J Cancer||28|92||bib21|'--><pub-id pub-id-type="pmid">1567700</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantel</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of survival data and two new rank order statistics arising in consideration</article-title><source>Cancer Chemother Rep</source><year>1966</year><volume>50</volume><fpage>163</fpage><lpage>170</lpage><!--PubMed citation query: 'Cancer Chemother Rep||50|163||bib22|'--><pub-id pub-id-type="pmid">5910392</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><collab>Medical Research Council Renal Cancer Collaborators</collab></person-group><article-title>Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>14</fpage><lpage>17</lpage><!--PubMed citation query: 'Lancet||353|14||bib23|'--><pub-id pub-id-type="pmid">10023944</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Hoogstraten</surname><given-names>B</given-names></name><name><surname>Staquet</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>A</given-names></name></person-group><article-title>Reporting results of cancer treatment</article-title><source>Cancer</source><year>1981</year><volume>47</volume><fpage>207</fpage><lpage>214</lpage><!--PubMed citation query: 'Cancer||47|207||bib24|'--><pub-id pub-id-type="pmid">7459811</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Tokue</surname><given-names>A</given-names></name></person-group><article-title>Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase</article-title><source>Cancer Chemother Pharmacol</source><year>1999</year><volume>44</volume><fpage>91</fpage><lpage>96</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||44|91||bib25|'--><pub-id pub-id-type="pmid">10412941</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name><name><surname>Caty</surname><given-names>A</given-names></name><name><surname>Lesimple</surname><given-names>T</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Rossi</surname><given-names>JF</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Gomez</surname><given-names>F</given-names></name></person-group><article-title>Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with and without fluorouracil</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>4009</fpage><lpage>4015</lpage><!--PubMed citation query: 'J Clin Oncol||18|4009||bib26|'--><pub-id pub-id-type="pmid">11118461</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>F</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Buclon</surname><given-names>M</given-names></name><name><surname>Perol</surname><given-names>D</given-names></name><name><surname>Lasset</surname><given-names>C</given-names></name></person-group><article-title>Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated with cytokines: a report from the Groupe Fran&#x000e7;ais d'Immunoth&#x000e9;rapie</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1460</fpage><lpage>1468</lpage><!--PubMed citation query: 'Ann Oncol||13|1460||bib27|'--><pub-id pub-id-type="pmid">12196373</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Lasset</surname><given-names>C</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Savary</surname><given-names>J</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Mercatello</surname><given-names>A</given-names></name><name><surname>Peny</surname><given-names>J</given-names></name><name><surname>Mousseau</surname><given-names>M</given-names></name><name><surname>Philip</surname><given-names>T</given-names></name><name><surname>Tursz</surname><given-names>T</given-names></name></person-group><article-title>Interleukin-2, interferon or both in 425 patients with metastatic renal cell cancer: results of a multicenter randomized trial</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1272</fpage><lpage>1278</lpage><!--PubMed citation query: 'N Engl J Med||338|1272||bib28|'--><pub-id pub-id-type="pmid">9562581</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>PA</given-names></name><name><surname>Vinke</surname><given-names>J</given-names></name><name><surname>Philip</surname><given-names>T</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Atzpodien</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>H</given-names></name><name><surname>Oskam</surname><given-names>R</given-names></name><name><surname>Franks</surname><given-names>CR</given-names></name></person-group><article-title>Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2</article-title><source>Ann Oncol</source><year>1992</year><volume>3</volume><fpage>475</fpage><lpage>480</lpage><!--PubMed citation query: 'Ann Oncol||3|475||bib29|'--><pub-id pub-id-type="pmid">1498066</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paolorossi</surname><given-names>F</given-names></name><name><surname>Villa</surname><given-names>S</given-names></name><name><surname>Barni</surname><given-names>S</given-names></name><name><surname>Tancini</surname><given-names>G</given-names></name><name><surname>Andres</surname><given-names>M</given-names></name><name><surname>Lissoni</surname><given-names>P</given-names></name></person-group><article-title>Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy</article-title><source>Tumori</source><year>1995</year><volume>81</volume><fpage>45</fpage><lpage>47</lpage><!--PubMed citation query: 'Tumori||81|45||bib30|'--></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>LM</given-names></name><name><surname>Tamm</surname><given-names>I</given-names></name></person-group><article-title>Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake</article-title><source>J Cell Physiol</source><year>1984</year><volume>121</volume><fpage>431</fpage><lpage>436</lpage><!--PubMed citation query: 'J Cell Physiol||121|431||bib31|'--><pub-id pub-id-type="pmid">6490733</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Audhuy</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>F</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Lesimple</surname><given-names>T</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Caty</surname><given-names>A</given-names></name><name><surname>Geoffrois</surname><given-names>L</given-names></name><name><surname>Ferrero</surname><given-names>JM</given-names></name><name><surname>Linassier</surname><given-names>C</given-names></name><name><surname>Drevon</surname><given-names>M</given-names></name><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name></person-group><article-title>Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>2728</fpage><lpage>2732</lpage><!--PubMed citation query: 'J Clin Oncol||16|2728||bib32|'--><pub-id pub-id-type="pmid">9704724</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>N&#x000e9;grier</surname><given-names>S</given-names></name><name><surname>Cany</surname><given-names>L</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Le Guillou</surname><given-names>M</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name><name><surname>Clavel</surname><given-names>M</given-names></name><name><surname>Gaston</surname><given-names>R</given-names></name><name><surname>Oskam</surname><given-names>R</given-names></name><name><surname>Philip</surname><given-names>T</given-names></name></person-group><article-title>Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma</article-title><source>Br J Cancer</source><year>1994</year><volume>69</volume><fpage>1111</fpage><lpage>1114</lpage><!--PubMed citation query: 'Br J Cancer||69|1111||bib33|'--><pub-id pub-id-type="pmid">8198979</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Seipp</surname><given-names>C</given-names></name><name><surname>Calabro</surname><given-names>S</given-names></name><name><surname>Karp</surname><given-names>SE</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Steinberg</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>DE</given-names></name></person-group><article-title>Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1863</fpage><lpage>1874</lpage><!--PubMed citation query: 'J Clin Oncol||7|1863||bib34|'--><pub-id pub-id-type="pmid">2685181</pub-id></citation></ref><ref id="bib35"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>PD</given-names></name><name><surname>Muss</surname><given-names>HB</given-names></name></person-group><article-title>Renal cell cancer</article-title><source>Biological Therapy of Cancer</source><year>1995</year><publisher-name>Philadelphia: JB Lippincott</publisher-name><fpage>373</fpage><lpage>387</lpage>De Vita VT, Hellman S, Rosenberg SA (eds) pp</citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tourani</surname><given-names>JM</given-names></name><name><surname>Pfister</surname><given-names>C</given-names></name><name><surname>Berdah</surname><given-names>JF</given-names></name><name><surname>Benhammouda</surname><given-names>A</given-names></name><name><surname>Salze</surname><given-names>P</given-names></name><name><surname>Monnier</surname><given-names>A</given-names></name><name><surname>Paule</surname><given-names>B</given-names></name><name><surname>Guillet</surname><given-names>P</given-names></name><name><surname>Chretien</surname><given-names>Y</given-names></name><name><surname>Brewer</surname><given-names>Y</given-names></name><name><surname>Di Palma</surname><given-names>M</given-names></name><name><surname>Untereiner</surname><given-names>M</given-names></name><name><surname>Malaurie</surname><given-names>E</given-names></name><name><surname>Tadrist</surname><given-names>Z</given-names></name><name><surname>Pavlovitch</surname><given-names>JM</given-names></name><name><surname>Hauteville</surname><given-names>D</given-names></name><name><surname>Mejean</surname><given-names>A</given-names></name><name><surname>Azagury</surname><given-names>M</given-names></name><name><surname>Mayeur</surname><given-names>D</given-names></name><name><surname>Lucas</surname><given-names>V</given-names></name><name><surname>Krakowski</surname><given-names>I</given-names></name><name><surname>Larregain-Fournier</surname><given-names>D</given-names></name><name><surname>Abourachid</surname><given-names>H</given-names></name><name><surname>Andrieu</surname><given-names>JM</given-names></name><name><surname>Chastang</surname><given-names>C</given-names></name></person-group><article-title>Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>2505</fpage><lpage>2513</lpage><!--PubMed citation query: 'J Clin Oncol||16|2505||bib36|'--><pub-id pub-id-type="pmid">9667271</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Herpen</surname><given-names>CM</given-names></name><name><surname>Jansen</surname><given-names>RL</given-names></name><name><surname>Kruit</surname><given-names>WH</given-names></name><name><surname>Hoekman</surname><given-names>K</given-names></name><name><surname>Groenewegen</surname><given-names>G</given-names></name><name><surname>Osanto</surname><given-names>S</given-names></name><name><surname>de Mulder</surname><given-names>PH</given-names></name></person-group><article-title>Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party</article-title><source>Br J Cancer</source><year>2000</year><volume>82</volume><fpage>772</fpage><lpage>776</lpage><!--PubMed citation query: 'Br J Cancer||82|772||bib37|'--><pub-id pub-id-type="pmid">10732744</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wadler</surname><given-names>S</given-names></name><name><surname>Westo</surname><given-names>R</given-names></name><name><surname>Weinberg</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>EL</given-names></name></person-group><article-title>Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects</article-title><source>Cancer Res</source><year>1990</year><volume>50</volume><fpage>5735</fpage><lpage>5739</lpage><!--PubMed citation query: 'Cancer Res||50|5735||bib38|'--><pub-id pub-id-type="pmid">1697499</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yagoda</surname><given-names>A</given-names></name><name><surname>Abi-Rached</surname><given-names>B</given-names></name><name><surname>Petrylak</surname><given-names>D</given-names></name></person-group><article-title>Chemotherapy for advanced renal-cell carcinoma: 1983&#x02013;1993</article-title><source>Semin Oncol</source><year>1995</year><volume>22</volume><fpage>42</fpage><lpage>60</lpage><!--PubMed citation query: 'Semin Oncol||22|42||bib39|'--></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer</article-title><source>Cancer J Sci Am</source><year>1997</year><volume>3</volume><fpage>S79</fpage><lpage>S84</lpage><!--PubMed citation query: 'Cancer J Sci Am||3|S79||bib40|'--><pub-id pub-id-type="pmid">9457400</pub-id></citation></ref></ref-list></back></article>


